For the expansion of oncology portfolio, Amgen announced to acquire Five Prime Therapeutics for approximately $1.9 billion. The transaction includes Bemarituzumab, a phase 3 Ready, first-in-class program for Gastric Cancer, the third leading cause of Cancer mortality globally.
- The acquisition of Five Prime also supports Amgen’s international expansion strategy.
- Amgen plans to leverage its presence in Japan and other Asia-Pacific markets to maximize bemarituzumab’s potential.
- Amgen will receive a royalty percentage on future net sales in Greater China ranging from the high teens to the low twenties from a pre-existing co-development and commercialization agreement between Five Prime and Zai Lab (Shanghai) Co., Ltd.
The prominent deals and partnerships by Amgen are featured below:
Sep 2020: The global pharma company Eli Lilly and Company announced a global antibody manufacturing collaboration with pharmaceutical leader Amgen to increase the supply capacity available for Lilly’s potential COVID-19 therapies.
July 2020: The leading independent biotechnology company Amgen announced an additional investment of approximately $421 million in BeiGene.
April 2020: Amgen, announced a collaboration with Adaptive Biotechnologies to address the COVID-19 pandemic. Both companies will combine their expertise to develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The companies have signed a MoU to enable the parties to begin work immediately.
March 2020: Amgen had completed the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013. AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K.
Amgen, headquartered in Thousand Oaks, California, the USA, is a worlds leading biotechnology company. The company was founded in 1980 and at present it has presence in approximately 100 countries. The company is committed to unlock the potential of biology by discovering, developing, manufacturing and delivering innovative human therapeutics. The company focuses on six therapeutic areas: cardiovascular disease, neuroscience, oncology, bone health, nephrology and inflammation.